Management ChangeMay 18, 2026, 08:01 AM
Kyverna Appoints Greg Martini as New CFO
AI Summary
Kyverna Therapeutics, Inc. announced the appointment of Greg Martini as its new Chief Financial Officer, effective May 18, 2026. Mr. Martini, previously SVP and CFO at Ironwood Pharmaceuticals, will lead Kyverna's financial strategy, capital allocation, and investor relations as the company advances its lead candidate, miv-cel, toward potential approval and commercialization. He succeeds Dr. Marc Grasso, who will provide consulting services for a smooth transition. In connection with his appointment, Mr. Martini received an inducement grant of an option to purchase 325,000 shares of common stock.
Key Highlights
- Kyverna Therapeutics appointed Greg Martini as Chief Financial Officer, effective May 18, 2026.
- Mr. Martini succeeds Dr. Marc Grasso, who will consult for a seamless transition.
- Martini will lead Kyverna's financial strategy, capital allocation, and investor relations.
- His appointment supports the advancement of miv-cel toward potential approval and commercialization.
- Martini previously served as Senior Vice President and CFO at Ironwood Pharmaceuticals.
- He led capital allocation, treasury, and investor relations at Ironwood, supporting commercial expansion.
- Mr. Martini received an inducement grant of an option to purchase 325,000 shares of common stock.
- The option vests over four years, with 25% on the one-year anniversary of his appointment.
Price Impact
More from KYTX